On May 28, the Federal Circuit reversed a PTAB inter partes review (“IPR”) decision that held Baxter Corporation Englewood’s (“Baxter’s”) claims were not invalid under 35 U.S.C. § 103(a) obviousness based on three prior art references: Alexander, Liff, and Morrison. The appeal involved telepharmacy technology for providing drug information to a pharmacist for approval while other non-pharmacists prepare the order. At issue on appeal were two limitations of the 8,554,579 (“579 patent”), referred to as the “verification limitation” […]

As telemedicine services and associated software platforms become more commonplace during the worldwide pandemic, healthcare entrepreneurs and technology companies are looking for ways to gain a competitive advantage in the marketplace. Intellectual property, particularly patents, are a powerful way to protect innovations and exclude competitors from using key features, but most telemedicine companies have not availed themselves of the full strategic potential offered by patents. This article discusses some new and different ways telemedicine […]